ENVB Stock Overview
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Enveric Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.93 |
| 52 Week High | US$6.98 |
| 52 Week Low | US$0.65 |
| Beta | 0.58 |
| 1 Month Change | 4.47% |
| 3 Month Change | 2.92% |
| 1 Year Change | -46.87% |
| 3 Year Change | -99.21% |
| 5 Year Change | n/a |
| Change since IPO | -99.56% |
Recent News & Updates
Shareholder Returns
| ENVB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.4% | 1.0% | -0.7% |
| 1Y | -46.9% | 11.6% | 22.3% |
Return vs Industry: ENVB underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: ENVB underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| ENVB volatility | |
|---|---|
| ENVB Average Weekly Movement | 26.1% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENVB's share price has been volatile over the past 3 months.
Volatility Over Time: ENVB's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Joseph Tucker | www.enveric.com |
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.
Enveric Biosciences, Inc. Fundamentals Summary
| ENVB fundamental statistics | |
|---|---|
| Market cap | US$6.86m |
| Earnings (TTM) | -US$17.46m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs ENVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENVB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.46m |
| Earnings | -US$17.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ENVB perform over the long term?
See historical performance and comparison